Company intelligence / Profile preview

StemBios Technologies, Inc.

Ownership
Private
Employees
~150
Development stage
Other
01

Overview

The company has discovered adult pluripotent stem cells (SB Cells®) from adult blood and bone marrow that have potential to act as embryonic stem cells without causing immune rejection or teratoma formation

Therapeutic areas
Metabolic DisordersOncologyImmunologyCardiovascularNeurology
Modalities
Stem cell therapyCell banking
Industry
Biotech
02

Drug pipeline

1 asset

SB cells-based cancer vaccine

Preclinical
03

Partnerships

Vitalia24

Beyond the preview

Go deeper on StemBios Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemBios Technologies, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call